The DOI matches its Crossref record.
Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1
Open accessAbstract
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) causes sensory loss that predominantly affects the lower limbs, often preceded by hyperpathia and spontaneous shooting or lancinating pain. It is caused by several missense mutations in the genes encoding 2 of the 3 subunits of the enzyme serine palmitoyltransferase (SPT). The mutant forms of the enzyme show a shift from their canonical substrate L-serine to the alternative substrate L-alanine. This shift leads to increased formation of neurotoxic deoxysphingolipids (dSLs). Our initial analysis showed that in HEK cells transfected with SPTLC1 mutants, dSL generation was modulated in vitro in the presence of various amino acids. We therefore examined whether in vivo specific amino acid substrate supplementation influenced dSL levels and disease severity in HSAN1. In mice bearing a transgene expressing the C133W SPTLC1 mutant linked to HSAN1, a 10% L-serine–enriched diet reduced dSL levels. L-serine supplementation also improved measures of motor and sensory performance as well as measures of male fertility. In contrast, a 10% L-alanine–enriched diet increased dSL levels and led to severe peripheral neuropathy. In a pilot study with 14 HSAN1 patients, L-serine supplementation similarly reduced dSL levels. These observations support the hypothesis that an altered substrate selectivity of the mutant SPT is key to the pathophysiology of HSAN1 and raise the prospect of l-serine supplementation as a first treatment option for this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sphingolipid metabolites in inflammatory disease
Maceyka, M., & Spiegel, S. (2014) · Nature · doi:10.1038/nature13475 · Cited by 1,277
Clinical implications of genetic advances in Charcot–Marie–Tooth disease
Rossor, A. M., Polke, J. M., Houlden, H., & Reilly, M. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.179 · Cited by 358
Le Douce, J., Maugard, M., Veran, J., Matos, M., Jégo, P., Vigneron, P.-A., Faivre, E., Toussay, X., Vandenberghe, M., Balbastre, Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.004 · Cited by 328
Oaklander, A. L., Herzog, Z. D., Downs, H. M., & Klein, M. M. (2013) · Pain · doi:10.1016/j.pain.2013.06.001 · Cited by 312
Serine restriction alters sphingolipid diversity to constrain tumour growth
Muthusamy, T., Cordes, T., Handzlik, M. K., You, L., Lim, E. W., Gengatharan, J., Pinto, A. F. M., Badur, M. G., Kolar, M. J., Wallace, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2609-x · Cited by 312
Metadata
- Authors
- Garofalo, K., Penno, A., Schmidt, B. P., Lee, H.-J., Frosch, M. P., von Eckardstein, A., Brown, R. H., Hornemann, T., & Eichler, F. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-12-01
- Volume
- 121
- Issue
- 12
- Pages
- 4735-4745
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2114268291
- Cited by
- 215
- References
- 0
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. https://app.cochat.ai/papers/10.1172/jci57549
- The paper
- Garofalo, K., Penno, A., Schmidt, B. P., Lee, H.-J., Frosch, M. P., von Eckardstein, A., Brown, R. H., Hornemann, T., & Eichler, F. S. (2011). Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. Journal of Clinical Investigation. https://doi.org/10.1172/jci57549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.